Speclipse Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 12

Employees

  • Latest Deal Type
  • IPO
  • (Cancelled)

  • Investors
  • 13

Speclipse General Information

Description

Developer of a medical diagnostic platform intended to detect early symptoms of skin cancer, including melanoma. The company's platform uses laser-induced plasma spectroscopy and machine learning to support non-invasive skin cancer diagnosis, enabling doctors to detect early-stage skin cancer without compromising efficacy or accuracy and reducing the need for biopsies.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4th Floor, Gyeongchang Building
  • 141, Unjung-ro, Bundang-gu
  • Seongnam-si, Gyeonggi-do
  • South Korea
+82
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Parent Company
Cell Return
Corporate Office
  • 4th Floor, Gyeongchang Building
  • 141, Unjung-ro, Bundang-gu
  • Seongnam-si, Gyeonggi-do
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Speclipse Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. IPO 19-May-2025 Cancelled Generating Revenue
7. Later Stage VC 28-Sep-2026 Completed Generating Revenue
6. Later Stage VC 01-Jul-2024 Completed Generating Revenue
5. Later Stage VC 21-Aug-2021 Completed Generating Revenue
4. Merger/Acquisition 04-Nov-2019 Completed Generating Revenue
3. Early Stage VC 18-Nov-2016 Completed Generating Revenue
2. Accelerator/Incubator 18-Dec-2015 Completed Startup
1. Accelerator/Incubator 01-Nov-2015 Completed Startup
To view Speclipse’s complete valuation and funding history, request access »

Speclipse Patents

Speclipse Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240219383-A1 Device, system, and method of measuring concentration of analyte in bodily fluid sample Inactive 28-Dec-2022
WO-2024143624-A1 Devices, system, and method for measuring concentration of analyte in body fluid sample Inactive 28-Dec-2022
EP-4364683-A1 Diagnostic device with probe including camera Pending 07-Nov-2022
US-12648813-B2 Diagnostic device with probe including camera Active 07-Nov-2022
US-20240148436-A1 Diagnostic device with probe including camera Active 07-Nov-2022 A61B5/0075
To view Speclipse’s complete patent history, request access »

Speclipse Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Speclipse Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bluepoint Venture Capital Minority
InterVest Venture Capital Minority
JB Investment (Seoul) Corporate Venture Capital Minority
Kite Entrepreneur Foundation Accelerator/Incubator
SBVA Venture Capital Minority
To view Speclipse’s complete investors history, request access »

Speclipse Acquisitions (1)

Speclipse’s most recent deal was a Merger/Acquisition with Korea Laser. The deal was made on 14-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Korea Laser 14-Jun-2023 Merger/Acquisition Therapeutic Devices
To view Speclipse’s complete acquisitions history, request access »

Speclipse FAQs

  • When was Speclipse founded?

    Speclipse was founded in 2015.

  • Where is Speclipse headquartered?

    Speclipse is headquartered in Seongnam-si, South Korea.

  • What is the size of Speclipse?

    Speclipse has 12 total employees.

  • What industry is Speclipse in?

    Speclipse’s primary industry is Diagnostic Equipment.

  • Is Speclipse a private or public company?

    Speclipse is a Private company.

  • What is Speclipse’s current revenue?

    The current revenue for Speclipse is .

  • How much funding has Speclipse raised over time?

    Speclipse has raised $33.8M.

  • Who are Speclipse’s investors?

    Bluepoint, InterVest, JB Investment (Seoul), Kite Entrepreneur Foundation, and SBVA have invested in Speclipse.

  • When was Speclipse acquired?

    Speclipse was acquired on 19-May-2025.

  • Who acquired Speclipse?

    Speclipse was acquired by Cell Return.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process